Versavo 400 mg contains Bevacizumab, a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF). It is widely used in oncology as part of combination therapy to control tumor progression.

🔬 Mechanism of Action

Bevacizumab binds to VEGF, preventing it from interacting with its receptors on endothelial cells. As a result, it:

• Inhibits angiogenesis (formation of new blood vessels)
• Reduces tumor blood supply
• Slows tumor growth and metastasis

This anti-angiogenic effect helps enhance the effectiveness of chemotherapy and other cancer treatments.

💊 Indications

Versavo 400 mg is indicated for:

• Metastatic Colorectal Cancer (mCRC)
• Non-Small Cell Lung Cancer (NSCLC)
• Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
• Cervical Cancer
• Glioblastoma (GBM)
• Other cancers as per approved clinical use

It is typically administered in combination with chemotherapy or targeted therapy.

📌 Key Features

• Strength: 400 mg
• Dosage Form: Intravenous infusion
• Therapeutic Class: Anti-VEGF Monoclonal Antibody
• Administration: IV infusion under oncology supervision
• Monitoring: Blood pressure, urine protein levels, and overall clinical monitoring required

⚕️ Benefits

• Targeted anti-angiogenic therapy
• Helps slow tumor progression
• Improves treatment outcomes when combined with chemotherapy
• Widely used across multiple cancer types

⚠️ Precautions

• Risk of hypertension and proteinuria
• Increased risk of bleeding and delayed wound healing
• Rare risk of gastrointestinal perforation
• Regular monitoring required during therapy
• Use strictly under oncologist supervision

Versavo 400 mg (Bevacizumab Injection) is an advanced targeted therapy that helps inhibit tumor angiogenesis and improve clinical outcomes in various cancers when used under specialized oncology care.